Compare RGEN & MBLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGEN | MBLY |
|---|---|---|
| Founded | 1981 | 1999 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 6.8B |
| IPO Year | 1995 | 2022 |
| Metric | RGEN | MBLY |
|---|---|---|
| Price | $114.25 | $7.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 19 |
| Target Price | ★ $173.09 | $16.17 |
| AVG Volume (30 Days) | 851.0K | ★ 3.6M |
| Earning Date | 04-28-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 286.96 | 87.43 |
| EPS | ★ 0.86 | N/A |
| Revenue | $141,236,000.00 | ★ $1,894,000,000.00 |
| Revenue This Year | $14.11 | $4.91 |
| Revenue Next Year | $14.71 | $14.09 |
| P/E Ratio | $136.56 | ★ N/A |
| Revenue Growth | ★ 35.10 | 14.51 |
| 52 Week Low | $102.97 | $7.49 |
| 52 Week High | $175.77 | $20.18 |
| Indicator | RGEN | MBLY |
|---|---|---|
| Relative Strength Index (RSI) | 32.73 | 35.00 |
| Support Level | $112.53 | N/A |
| Resistance Level | $132.51 | $9.74 |
| Average True Range (ATR) | 4.78 | 0.30 |
| MACD | 0.35 | 0.02 |
| Stochastic Oscillator | 11.36 | 13.33 |
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. The company's reportable operating segment are Mobileye and Moovit. Its solutions comprise Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It derives maximum revenue from Mobileye Segment.